For the roughly 2 to 3 million Americans living with treatment-resistant depression, the question is not whether a psilocybin-based therapy will eventually reach the market — the clinical data already strongly suggest it will — but when, specifically, it might become available to them.
Compass Pathways’ synthetic psilocybin treatment, COMP360, remains the most clinically advanced psychedelic therapy currently in the FDA’s pipeline. With a New Drug Application submission targeted for the fourth quarter of 2026 and a National Priority Voucher granting a compressed one-to-two-month review window, a realistic timeline for final FDA approval points to early 2027 — though initial access would almost certainly be limited to specialized treatment centers rather than a typical pharmacy prescription.
Why This Matters
Treatment-resistant depression — defined as depression that has not responded to at least two adequate courses of standard antidepressant treatment — leaves patients with genuinely limited options. Existing FDA-approved treatments for this population, including esketamine (Spravato) and lithium augmentation, work for some patients but not all, and both carry significant limitations in either administration burden or side effect profile.
For patients and families who have been following psilocybin therapy research with cautious hope, having a specific, evidence-based timeline — rather than vague anticipation — allows for more realistic planning and expectation-setting, both for the people directly affected and for the physicians who will eventually need to prepare to offer this treatment.
What We Know So Far
Compass Pathways has achieved two consecutive positive Phase 3 trial results for COMP360 in treatment-resistant depression: COMP005 in June 2025 and COMP006 in February 2026, both hitting their primary endpoints with high statistical significance. This consecutive Phase 3 success is itself historically significant — it represents the first time any classic psychedelic compound has achieved this milestone for a psychiatric indication in U.S. regulatory history.
Following President Trump’s April 18, 2026 executive order directing federal agencies to accelerate review of psychedelic drug therapies, the FDA issued a National Priority Voucher to Compass Pathways’ COMP360 program on April 24, 2026. This voucher mechanism can compress the FDA’s standard 10-to-12-month drug application review timeline down to just one to two months once a complete New Drug Application is submitted.
Compass Pathways has stated it is pursuing a rolling NDA submission, with components of the application already submitted to the FDA, and the complete submission targeted for the fourth quarter of 2026.
Building the Realistic Timeline
Working through the publicly stated milestones provides a clear basis for timeline expectations:
Q4 2026 (October–December): Compass Pathways completes its rolling NDA submission to the FDA. This is the company’s own stated target.
Roughly 1–2 months after complete submission: Under the National Priority Voucher mechanism, the FDA’s review and decision could follow within this compressed window — meaning a final approval or rejection decision could plausibly land anywhere from late 2026 to February or March 2027, depending on exactly when in Q4 the complete submission lands and how the FDA’s review proceeds.
If approved, before commercial availability: Two additional steps would need to occur before patients could actually access the treatment. First, the FDA would need to finalize Risk Evaluation and Mitigation Strategy (REMS) requirements, since COMP360 is expected to be approved only for use in certified, supervised clinical settings with trained therapists present — not as a take-home prescription. Second, COMP360 remains a Schedule I controlled substance; the DEA would need to complete a rescheduling process, which the April 18 executive order specifically directed the agency to initiate and complete as quickly as possible once Phase 3 data supported it.
Taken together, a plausible and reasonably well-supported estimate places final FDA approval in the early 2027 window — with actual patient access likely following some additional weeks to months after that, as REMS-certified treatment centers come online and DEA rescheduling is finalized.
What Access Will Likely Look Like at First
This is the piece of the timeline that matters most for patient expectation-setting: even after approval, COMP360 will not be available the way a standard antidepressant prescription is filled at a local pharmacy.
Based on the clinical trial protocol and the REMS framework anticipated for this drug class, COMP360 treatment would involve one to three supervised dosing sessions in a certified clinical setting, with preparation sessions before dosing and integration sessions afterward, administered only by trained, certified therapists at REMS-certified treatment centers.
Compass Pathways has indicated it expects centers currently delivering esketamine (Spravato) — which already operates under a comparable REMS structure requiring in-office supervised administration — to be well-positioned to also become certified COMP360 treatment sites. This existing esketamine treatment center network could meaningfully accelerate the practical rollout of access once FDA approval and REMS finalization occur, since the infrastructure and certification processes share significant overlap.
What Doctors and Experts Say
Kabir Nath, CEO of Compass Pathways, has described the FDA’s National Priority Voucher as validation of both the clinical need and the science behind COMP360, and has pointed to the existing esketamine treatment network as a meaningful head start for access infrastructure once approval is achieved.
Mental health policy researchers, including those at Harvard’s Petrie-Flom Center, have noted that while the voucher mechanism represents a genuinely novel and significant acceleration of the regulatory pathway, it does not itself guarantee approval — the FDA’s final decision will still depend on its full review of the complete NDA submission, including all safety and efficacy data.
What the Evidence Shows — and What It Does Not
MedicalDaily Evidence Check
- Clinical data: Two consecutive positive Phase 3 trials (COMP005, COMP006), both meeting primary endpoints with high statistical significance, covering more than 1,000 combined trial participants
- Regulatory mechanism: National Priority Voucher granted April 24, 2026, compressing standard FDA review from 10–12 months to 1–2 months post-submission
- Stated company timeline: Complete NDA submission targeted for Q4 2026
- What remains uncertain: The exact submission date within Q4 2026, which directly affects the resulting approval timeline; whether the FDA’s review identifies any issues requiring additional data or delaying approval; the specific timeline for DEA rescheduling completion; the pace at which REMS-certified treatment centers will become operational after approval
- What this is not: A guarantee of approval — the FDA’s decision still depends on its independent review of the complete application
Who Should Pay Attention to This Timeline
- Adults with treatment-resistant depression (failed at least two adequate antidepressant courses) who are interested in psilocybin therapy as a future option
- Psychiatrists and mental health treatment centers, particularly those currently offering esketamine (Spravato), who may want to begin considering future REMS certification planning
- Family members and caregivers of people with treatment-resistant depression who are tracking emerging treatment options
What You Can Do Now
- COMP360 is not yet approved and remains Schedule I — do not seek psilocybin therapy through unregulated sources in anticipation of future approval, as these carry both legal and health risks.
- If you have treatment-resistant depression, continue working with your psychiatrist on currently available FDA-approved options, including esketamine (Spravato), while this regulatory process unfolds.
- Follow Compass Pathways’ investor communications and the FDA’s Drug Approval Package database for confirmation of the Q4 2026 NDA submission completion, which will be the next concrete milestone to watch.
- If you live in Oregon or Colorado, state-level supervised psilocybin therapy programs are already legally operating independently of the FDA approval process, though they are not covered by insurance.
What Happens Next
Compass Pathways’ rolling NDA submission is expected to be completed in Q4 2026. Following complete submission, the FDA’s compressed one-to-two-month review timeline under the National Priority Voucher would apply. In parallel, REMS framework development and DEA rescheduling processes will need to be finalized before patients can access an approved treatment. MedicalDaily will report on each milestone as it is reached, including the NDA submission completion and any FDA decision.
The Bottom Line
Based on Compass Pathways’ stated Q4 2026 submission target and the FDA’s National Priority Voucher compression of the review timeline, early 2027 represents a realistic, evidence-based window for a potential historic first approval of a psychedelic therapy in the United States. For patients waiting now, the most useful planning assumption is this: approval could plausibly arrive within the next six to nine months, but actual treatment access — through certified centers with trained therapists, similar to the existing esketamine model — will likely take additional time beyond the approval date itself.
